...Good morning, everyone. I think we're going to ask those of you here in the room to please take your seats, and we're going to get started. Welcome to Caribou Bioscience's KOL panel at ASH 2025. My name is Rachel Haurwitz. I'm the President and CEO of Caribou, and it's my great pleasure to welcome you here, both the people here in the room with us in Orlando today, as well as the many who are listening online to our webcast. As we dive in -- I would like to advance the slides. There we go. As we dive in, I would like to acknowledge that this presentation includes important information as well as forward-looking statements. Our speakers have several disclosures which are summarized here. We are so grateful to be joined today by four physicians who are going to bring their unique perspectives on the unmet need faced by their patients and the role that vispa-cel could play in bringing the benefit of cell therapy to more lymphoma patients. Today we're going to focus on vispa-cel, Caribou's...